A POC and Dose-Ranging Study of HTD1801 in PSC Patients
Status:
Completed
Trial end date:
2020-08-14
Target enrollment:
Participant gender:
Summary
This study evaluates HTD1801 in the treatment of Primary Sclerosing Cholangitis (PSC) in
adults. The subjects will be randomised to 3 treatment groups, to receive 500mg, 1000mg and
placebo, bid.